Form D · Pharmaceuticals
Confluence Pharmaceuticals LLC
Carmel, IN · CIK 0001689048
Offering snapshot reported Oct 4, 2018 · SEC filing
- Reported sold
- $10K Offering amount: $800K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Sep 17, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 4, 2018 | Initial | $10,000 | No comparison | 1 | SEC filing |
| Nov 7, 2016 | Initial | $1,284,998 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-322791
Promissory notes convertible into preferred units
Source: Form D, filed Oct 4, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven L. Johns | Director, Executive |
| Phil Lodato | Director |
| Boyd W. Sturdevant, Jr. | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4904 Deer Ridge Drive South
Carmel, IN, 46033
Carmel, IN, 46033